112 related articles for article (PubMed ID: 33105923)
21. [Progress, challenges and countermeasures of global hepatitis C elimination].
Chen ZD
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):812-816. PubMed ID: 33105922
[TBL] [Abstract][Full Text] [Related]
22. [Elimination of hepatitis C, our progress, challenges and hopes].
Rao HY; Li MY; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):809-811. PubMed ID: 33105921
[TBL] [Abstract][Full Text] [Related]
23. [Current status, treatment and prospect of patients with chronic hepatitis C genotype 3 in China].
Wang XZ; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):824-826. PubMed ID: 33105925
[TBL] [Abstract][Full Text] [Related]
24. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
Jonas MC; Loftus B; Horberg MA
Infect Dis Clin North Am; 2018 Jun; 32(2):481-493. PubMed ID: 29778267
[TBL] [Abstract][Full Text] [Related]
25. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
26. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey.
Kim HS; Yang JD; El-Serag HB; Kanwal F
J Viral Hepat; 2019 May; 26(5):596-602. PubMed ID: 30629790
[TBL] [Abstract][Full Text] [Related]
27. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States.
Ward JW
Clin Liver Dis; 2013 Feb; 17(1):1-11. PubMed ID: 23177279
[TBL] [Abstract][Full Text] [Related]
28. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine.
Stasi C; Silvestri C; Voller F; Cipriani F
J Infect Public Health; 2016; 9(4):389-95. PubMed ID: 26148849
[TBL] [Abstract][Full Text] [Related]
29. Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China.
Song Y; Li Y; Cheng H; Du X; Mi J; Le LV; Chen Z; Chan P; Sun J
Infect Dis Ther; 2022 Aug; 11(4):1427-1442. PubMed ID: 35821355
[TBL] [Abstract][Full Text] [Related]
30. [Quality evaluation of hospitalized hepatitis C cases reporting in Henan province, 2014].
Li J; Yang W; Liang Y; Fan P; Li N; Sun D; Zhu Q; Wang Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Oct; 36(10):1129-33. PubMed ID: 26837359
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities.
Perumalswami PV; Factor SH; Kapelusznik L; Friedman SL; Pan CQ; Chang C; Di Clemente F; Dieterich DT
J Hepatol; 2013 May; 58(5):890-7. PubMed ID: 23333446
[TBL] [Abstract][Full Text] [Related]
32. Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care.
Lebovics E; Torres R; Porter LK
Am J Med; 2017 Feb; 130(2):S1-S2. PubMed ID: 28087291
[TBL] [Abstract][Full Text] [Related]
33. Urgency to treat patients with chronic hepatitis C in Asia.
Kao JH; Ahn SH; Chien RN; Cho M; Chuang WL; Jeong SH; Liu CH; Paik SW
J Gastroenterol Hepatol; 2017 May; 32(5):966-974. PubMed ID: 28005275
[TBL] [Abstract][Full Text] [Related]
34. Toward the elimination of hepatitis C in the United States.
Saab S; Le L; Saggi S; Sundaram V; Tong MJ
Hepatology; 2018 Jun; 67(6):2449-2459. PubMed ID: 29181853
[TBL] [Abstract][Full Text] [Related]
35. [Related factors for severe liver fibrosis in chronic hepatitis C patients with remunerated blood donation history in Jurong of Jiangsu province].
Yao YN; Huang P; Chen HB; Zhang L; Chen MZ; Yu RB
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jan; 38(1):49-52. PubMed ID: 28100376
[No Abstract] [Full Text] [Related]
36. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.
Lazarus JV; Safreed-Harmon K; Thursz MR; Dillon JF; El-Sayed MH; Elsharkawy AM; Hatzakis A; Jadoul M; Prestileo T; Razavi H; Rockstroh JK; Wiktor SZ; Colombo M
Semin Liver Dis; 2018 Aug; 38(3):181-192. PubMed ID: 29986353
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
38. [Natural clearance of hepatitis C virus in 96 patients with infection acquired by blood transfusion from a single donor in Guizhou].
Liu S; Cheng M; Mu M; Yang Q
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):251-4. PubMed ID: 25173221
[TBL] [Abstract][Full Text] [Related]
39. Barriers to hepatitis C virus treatment in Guangdong Province.
Yang X; Xu Z; Mei Y; Lin G; Wei J; Shao X; Luo Q; Zhao Z; Lin C; Zhang X
Ann Palliat Med; 2019 Nov; 8(5):640-644. PubMed ID: 31865724
[TBL] [Abstract][Full Text] [Related]
40. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
